**Microspheres: A Novel Drug Delivery System**

Nikita Patil, Pooja Patil, Abhishek Patil and Mrs. Shraddha N. Bhavasar
Department of Pharmaceutics, Matoshri College of Pharmacy, Nashik.

---

**Manuscript Info**

**Manuscript History**
Received: 25 October 2021
Final Accepted: 29 November 2021
Published: December 2021

---

**Abstract**

Microspheres are freeflowing powders that are made up of proteins or synthetic polymers. They are little spherical particles with diameters ranging from a few millimetres to a few millimetres (typically from 1 to 100 micrometers). Microspheres are microparticles that are employed in applications that require a predictable and constant particle surface area. To achieve the desired impact, the drug should be delivered in an ideal amount at the right time to the target tissue with the least degree of adverse effects and maximal therapeutic efficacy. The microspheres drew a lot of attention because of their long-lasting release and ability to target anticancer medications to the tumor. Microspheres will play a key role in innovative medication delivery in the future, particularly in sick cell sorting, diagnostics, gene & genetic materials, and safe, targeted and precise delivery.

---

**Introduction:**

Microspheres are tiny spherical particles having dimensions in the micrometer range (usually 1 to 1000 micrometers). Microparticles are another name for microspheres. Natural and manmade materials can be used to create microspheres. Commercially accessible microspheres include glass, polymer, and ceramic microspheres. Solid and hollow microspheres have various densities and are utilised for different purposes. Hollow microspheres are commonly utilised as additions to reduce a material's density. Depending on the type of substance and size of the material, solid microspheres can be used for a variety of purposes. Microspheres are designed to address some of the issues with traditional therapy and to improve the therapeutic efficacy of a specific medicine.

**Two most common types of polymer**
1. Polyethylene microspheres
2. Polystyrene microspheres

**Polyethylene microspheres:**
Microspheres made of polyethylene are often employed as permanent or temporary fillers. Polyethylene microspheres with a lower melting point can generate porous architectures in ceramics and other materials. Polyethylene microspheres are very sought for flow visualisation and fluid flow analysis, microscopy techniques, health sciences, process troubleshooting, and other research applications due to their high sphericity and availability of colourful and fluorescent microspheres. Electronic paper digital displays also use charged polyethylene microspheres.
Polystyrene microspheres:
Polystyrene microspheres are frequently employed in biological applications because they make operations like cell sorting and antibody precipitation easier. Proteins and ligands rapidly and permanently adsorb onto polystyrene microspheres, making them ideal for medical research and biological laboratories.

Theory
Types Of Microspheres
Bioadhesive microspheres:
Adhesion is defined as the ability of a medication to adhere to a membrane using its sticking feature polymers that are water soluble. Drug delivery device adhesion to mucosamembrane. Bioadhesion can be described as buccal, ocular, rectal, nasal, and other types of adhesion. The term “bioadhesion” refers to the ability of cells to stick together. Materials that bind to biological substrates, such as mucosal members, are referred to as mucosal members. The ability to attach bioadhesive drug delivery devices to mucosal tissue allows for the creation of an implant. The frequency of administration was reduced, which increased patient compliance. By combining the two, it provides an intelligent way to drug delivery.

Magnetic microspheres:
This type of delivery mechanism is critical because it allows the drug to be delivered to the illness location. A higher amount of freely circulating medicine can be substituted with a smaller amount of magnetically focused drug in this situation. Magnetic carriers receive magnetic responses to a magnetic field from integrated components such as chitosan, dextran, and other materials utilized in magnetic microspheres. The many types are as follows: Magnetic microspheres are utilized to deliver therapeutic drugs.

To treat a liver tumour, a chemotherapeutic drug is used. This technique can also target drugs such as proteins and peptides. The magnetic drug transport technology is based on the fact that the drug can be encapsulated or conjugated on the surface of a magnetic microsphere. The carrier’s accumulation at the target spot allows them to deliver the drug locally.

Floating microspheres:
Because floating types have a lower bulk density than gastric fluid, they float in the stomach without slowing down gastric emptying. When the system is floating on stomach content, the medicine is released slowly and at an ideal rate, resulting in increased gastric residence and plasma concentration oscillations. It also reduces the chances of striking and dose dumping while providing a long-term therapeutic impact. This is how the medication (ketoprofen) is given.

Radioactive Microspheres:
Microspheres used in radioemobilisation therapy range in size from 10 to 30 nanometers, which are larger than capillaries. When they come across, they get tapped in the first capillary bed. They are injected into the arteries leading to the tumour. As a result, these radioactive microspheres give a substantial dosage of radiation to the body.

They are injected to the arteries that lead to tumour of interest. So, these radioactive microspheres deliver high radiation dose to the targeted areas without damaging the normal surrounding tissues. It differs from drug delivery system, as radio activity is not released from microspheres but acts from within a radioisotope typical distance and the different kinds of radioactive microspheres are α emitters, β emitters, γ emitters.

Mucoadhesive microspheres:
Mucoadhesive microspheres with a diameter of 1-1000nm and made entirely of or coated with a mucoadhesive polymer have additional advantages, including efficient drug absorption and increased bioavailability due to a high surface to volume ratio, much closer contact with the mucus layer, and specific drug targeting to the absorption site achieved by anchoring plant lecti. Mucoadhesive microspheres can be modified to adhere to any mucosal tissue, such as that present in the eye, nasal cavity, urinary tract, and gastrointestinal tract, allowing for both localised and systemic controlled pharmaceutical release.

Material:
Microspheres used usually are polymers. They are classified into two types:
Synthetic Polymers
Natural polymers
Synthetic polymers are divided into two types.
a) Non-biodegradable polymers
Poly methyl methacrylate (PMMA), Acrolein, Glycidyl methacrylate, Epoxy polymers
b) Biodegradable polymers
Lactides, Glycolides& their co polymers, Poly alkyl cyanoacrylates, Poly anhydrides

Natural polymers obtained from different sources like proteins, carbohydrates and chemicallymodified carbohydrates.

Proteins: Albumin, Gelatin, Collagen

Carbohydrates: Agarose, Carrageenan, Chitosan, Starch

Chemically modified carbohydrates: Poly dextran, Poly starch.

Method of Preparation
The choice of technique depends upon the nature of polymer as well nature of drug and the duration of therapy. The most important physical chemical factors that may be controlled in microsphere manufacture are:

1. The particle size requirement
2. Molecular weight of polymer
3. Polymer to drug ratio
4. No stability problem
5. Final product should be non-toxic.
6. Total mass of drug and polymer
7. Reproducibility
8. Controlled particle size and dispersibility in aqueous vehicles for injection
9. Release of active reagent with a good control over a wide time scale

Techniques for microsphere preparation
1. Single emulsion techniques
2. Double emulsion techniques
3. Polymerization
   a. Normal polymerization
      1. Bulk
      2. Suspension
      3. Emulsion
   b. Inter-facial polymerization
      4. Phase separation coacervation technique
      5. Spray drying
      6. Solvent extraction
      7. Solution-enhancement dispersion method
      8. Wax coating Hot-melt method

Single emulsion technique
There are several Proteins and carbohydrates, which are prepared by this technique. In which the natural polymers are dissolved in aqueous medium and the followed by dispersion in oil phase i.e. non-aqueous medium.
Double emulsion technique
It is the preparation of multiple emulsions, i.e. W/O/W, by pouring the primary w/o emulsion into aqueous poly vinyl alcohol solution. This w/o/w emulsion required 30 minutes of steady churning. Over the course of 30 minutes, gradually add some water to the emulsion. Microcapsules are collected through filtration and dried under vacuum. Water soluble medicines, peptides, proteins, and vaccinations are the best candidates. This approach can be used with both natural and synthetic polymers. A lipophilic organic continuous phase disperses the aqueous protein solution. The active components may be present in this protein solution. Disperse in oil/organic phase homogenization/vigorous, i.e. production of first emulsion followed by addition to an aqueous solution of PVA (Poly Vinyl Alcohol), resulting in several emulsions.

Polymerization techniques
Mainly two techniques are using for the preparation of microsphere are classified as:

(a) Normal polymerization
To commence polymerization in bulk polymerization, a monomer or a combination of monomers, as well as the initiator or catalyst, is commonly heated. The resulting polymer can be moulded into microspheres. Drug loading can be accomplished by adding the drug during the polymerization process. It is particularly difficult to dissipate the heat of reaction, which impacts thermo labile active components, even if it is a pure polymer synthesis process. Suspension polymerization, also known as pearl polymerization, involves heating the monomer mixture with active medication as droplets dispersion in a continuous aqueous phase at a lower temperature. Microspheres having a diameter of less than 100 m are created through suspension methods.

(b) Interfacial polymerization
The creation of a polymer film that effectively envelops the dispersed phase is caused by the interaction of various monomers at the interface between the two immiscible liquid phases. In this method, two reactive monomers are used: one is dissolved in continuous phase, while the other is disseminated in continuous phase (aqueous in nature) and emulsified throughout. Two situations arise due to the solubility of the generated polymer in the emulsion droplet. The carrier will be monolithic if the polymer is soluble in the droplet. The capsular kind is formed when the polymer is insoluble in the droplet.

Spray drying and spray congealing
Concept of spray drying technique depending upon the removal of solvent or the cooling of solution the two processes are spray drying & spray congealing is shown in the figure below. Evaporation is the basic mechanism in spray drying, whereas in spray congealing it is that of a phase inversion from a liquid to a solid. Both processes are similar, except for energy flow. Spray drying is the most widely used industrial process involving particle formation and drying.

Therefore, spray drying is an ideal process where the endproduct must comply with precise quality standards regarding particle size distribution, residual moisture content, bulk density, and particle shape.
Spray drying technique is also useful for preparing chitosan microsphere. In 1999 He et.al. Used formaldehyde as a crosslinking and also reported a novel method in which cimetidine and famotidine were entrapped in microspheres prepared by spray drying of multiple emulsion (o/w/o or w/o/w). They found that the release of the drugs from microspheres by this novel method was significantly sustained as compared to those prepared by conventional spray drying or o/w emulsion method.

Wax Coating and Hot Melt
Polymer is dispersed in a suitable dispersion media and then slowly cooled to generate microspheres in this procedure. This technology can easily manufacture polymers with low melting points into microspheres. Particle wax is mostly used for coating and coring. In which the medication is encapsulated by dispersion in moulded wax. High-speed mixing disperses the wax suspension in a cold solution, such as liquid paraffin. For one hour, agitate the mixture. The exterior phase was then decanted, and suspended microspheres were collected from the solvent. Allow it to dry in the open air. It is a less expensive way than others, and the medicine is released faster. Carnauba wax and beeswax are the most common coating ingredients, and they can be blended to create custom coatings in order to achieve desired characteristics.

Solvent evaporation method
For the generation of emulsions between a polymer solution and an immiscible continuous phase in both aqueous (o/w) and non-aqueous (w/o) environments. Bogataj et al. (2000) used the evaporation method to manufacture microspheres using liquid paraffin/acetone as the solvents. The drug solution (in acetone) was distributed in chitosan solution, which was then emulsified and mixed in liquid paraffin. The microsphere suspension was filtered, washed, and dried. Magnesium stearate was also used as an agglomeration-preventative agent. The average particle size decreased as the amount of magnesium stearate employed for microsphere preparation increased.
Phase separation coacervation technique
It is the straightforward separation of two immiscible liquid phases from a micromolecular solution. The polymer is solubilized in this process to create a solution. This method is used to produce reservoir-type systems, such as encapsulating water-soluble medicines like peptides and proteins. The objective of coacervation is to reduce the polymer's solubility in the organic phase in order to affect the creation of polymer-rich phases known as coacervates. In this approach, drug particles are dispersed in a polymer solution, and an incompatible polymer is added to the system, causing the first polymer to phase separate and swallow the drug particles. This process can also be used to make matrix-type preparations for hydrophilic drugs such as steroids. Adding non-solvent results in matrix-type preparations.

Solvent extraction
The organic phase is removed by extraction of the organic solvent in this process of microparticle production. Isopropanol can be used as an organic solvent that is water miscible. Organic phase is removed by water extraction. This procedure can shorten the time it takes for a microsphere to harden. Direct addition of the medication or protein to the polymer organic solution is one version of the method. The rate of solvent removal by extraction relies on the temperature of the water, the emulsion volume to water ratio, and the polymer's solubility profile.

Emulsification method
Multiple emulsions may also be formed for example; a heated aqueous drug solution can be dispersed in molten wax to form a water-in-oil emulsion, which is emulsified in a heated external aqueous phase to form a water-in-oil-in-water emulsion. The system is cooled and the microcapsules collected. For highly aqueous soluble drugs, a nonaqueous phase can be used to prevent loss of drug to the external phase. Another alternative is to rapidly reduce the temperature when the primary emulsion is placed in the external aqueous phase.

Mechanism of Drug Release
Various events and mechanisms (dissolution/diffusion, osmotically driven release, erosion) contribute to the drug release of microparticulates manufactured by particular manufacturing technologies and/or possibly incorporating
special excipient(s). In most cases, these processes operate in tandem, with one playing a larger role during drug release than the other.

The behaviour of the polymer system during dissolution is crucial when the active medicinal ingredient is incorporated in a polymer matrix in a microparticulate, but it is reliant on a number of characteristics (drug properties, formulation, release medium, etc.)

In the case of a polymer matrix, the active ingredient can diffuse across the entire polymer network or through the holes filled with water. Aqueous pore networks may dissolve drugs that dissolve in water.

Polymer chains swell as a result of water absorption, indicating the creation of new holes and/or osmotic pressure. Swelling raises the volume, the drug's effective diffusion coefficient rises, and more pharmakon molecules enter the watery component. It's also conceivable for the polymer matrix (bulk/surface) to erode.

The initial "burst" of drug, which can be as much as 10–50 percent of the drug load, is followed by a "lag" phase of delayed release, and then a period of steady release for macromolecules. The first wave of protein-based therapies has been linked to their proclivity for partitioning to the surface of the microsphere during the process of encapsulation. Attempts have been made to alleviate the burst using a variety of methods.
To minimize the affinity of the encapsulated pharmaceuticals for the bulk phase, add excipients to the polymer phase, employ innovative polymers, encapsulate particulate versions of the drugs, or replace the non-solvent aqueous phase used in the construction process with non-polar oils or alcohols. The explosion is frequently followed by a period of restricted dissemination and little activity.

**Formulation and Manufacturing**

**Composition and Excipients**

Plant, animal, and microbial-origin biopolymers are advantageous, as are semi-synthetic cellulose derivatives and biodegradable or non-biodegradable synthetic polymers. Polysaccharides and proteins are commonly included in the formulation, but waxes and lipids also play a role. Non-polymer excipients help construct and solidify the polymer network of drug delivery systems by crosslinking polymer chains (CaCl₂, glutaraldehyde, poly-l-lysine, etc.).

The most commonly used polymers and their important microencapsulation-related properties are summarized in Table.

| Excipient | Physiochemical Properties | Applications and Benefits | Limitations | Ref. |
|-----------|--------------------------|---------------------------|-------------|------|
| Gelatine  | Amphoteric gelatin A (isoelectric point (IEP) pH: 7–9.4) gelatin B (IEP: pH 4.8–5.5) Swells, then dissolves in water | At low pH coacervation with negatively charged polymers, high potential of crosslinking emulsifier, stabilizer (high viscosity), binder Thermoreversible gelling, implantable pulmonary delivery | Influence of pH and ionic strength on behavior Need for preservation against possible prion (BSE) contamination | 20,21 |
| Substance         | Properties                                      | Applications                                           | Notes                                      |
|-------------------|-------------------------------------------------|-------------------------------------------------------|--------------------------------------------|
| Caesin            | pH-dependent, swelling, dissolution, erosion    | calcium caseinate – reversible thermal gelation        | Anaphylactic Reactions                     |
|                   |                                                  | solubility increase (coenzyme Q10)                    |                                            |
| Whey Protein      | Insoluble at its IEP (pH 5.2)                   | Thermal gelation, encapsulation of oils                | Thermally irreversible gel formation above |
|                   |                                                  | film formation: gas barrier, good tensile strength    | 70 °C                                      |
|                   |                                                  |                                                       | Denatures at higher salt conc.            |
| Albumin           | IEP: 4.7 Freely soluble in water negative charge at pH 7.4 | Pulmonary delivery Alginate-albumin                   | Chemical degradation, denaturation at high |
|                   |                                                  |                                                       | salt conc., enzymes, heat                 |
| Zein              | α, β, γ, δ, zein with different Mw amphiphilic character. | Oral controlled release matrix and wall                | Brittle, rigid wall, complex with a       |
|                   |                                                  |                                                       | gelling component to plasticize          |
| Soy Protein       | Partly Soluble in water depending on extraction process | Oral control release matrix and wall emulsifier, foaming agent | Sensitivity                              |
| Gluten            | Water insoluble                                 | Wall material, good elastic and thermoplastic properties | Gluten sensitivity                      |
| Bees-wax (Apismellifera) | Melting point 62-64 C HLB = 12 | Edible, easy use, smooth surface, hot melt extrusion prolonged release for hydrophilic substances, protection from chemical degradation | Oxidation                               |
| Carnauba wax (Copernicacerifera) | mp: 78–85 °C HLBrequired = 12 | Good compatibility hot melt extrusion, embedding water soluble components, taste masking | Oxidation                               |
| Paraffin (hard mineral) | mp: 50-60 C | Embedding water soluble components liquid paraffin in the emulsification | Sensitivity                              |
| Material                  | Properties                                                                 | Process                                                                                     | Notes                                                                 |
|--------------------------|-----------------------------------------------------------------------------|----------------------------------------------------------------------------------------------|----------------------------------------------------------------------|
| Chitosan                 | Soluble in weak acids. Mucoadhesive reacts with negatively charged surfaces | Antifungal, antibacterial, reduces LDL (low-density lipoprotein), tissue regenerative, pulmonary delivery. Ionotropic gelation, coacervation with anions, modified emulsification. | pH dependence (insoluble above pH 6.5). Addition of electrolytes precipitates chitosan in solution, hygroscopic. pH dependence (insoluble above pH 6.5). Addition of electrolytes precipitates chitosan in solution, hygroscopic. |
| Sodium hyaluronate       | Anionic character, soluble in water, high viscosity at low concentration    | In microspheres nasal, vaginal, ophthalmic delivery systems                                | Very hygroscopic, when heated, emits Na2O. Very hygroscopic, when heated, emits Na2O. |
| Starch (wheat, corn, potato, rice, tapioca) | Starch from different origins. Differ in particle size and shape. Soluble in hot water after a time of gelatinization. | Spray drying, extrusion, molecular inclusion, coacervation with proteins, hydrocolloid-forming, release via swelling, diffusion, erosion. | Hygroscopic. Hygroscopic. |
| Gaur gum                 | Water soluble, nonionic, galactomannan forms a thixotropic solution, stable at pH 4–10.5. | Controlled-release, colon-targeted release, appetite suppressant, thermoreversible. Needs preservation, borate hinders swelling. | Needs preservation, borate hinders swelling. Needs preservation, borate hinders swelling. |
| Locust bean gum (LBG)/carob, ceratonia | Nonionic, galactomannan, dispersible in hot water, soluble at higher temperature. | Controlled release in combination pseudoplastic, gelling with the addition of borate, solubility not affected by pH or ionic concentration. Low water solubility, hypersensitivity. | Low water solubility, hypersensitivity. Low water solubility, hypersensitivity. |
| Konjac Gum               | Water soluble.                                                              | Elevation of temperature, increase gelation, antioxidant properties.                        | Indigestible. Indigestible. Indigestible. |
| Carrageenan              | Anionic polymer, τ-Carrageenan: shear thinning thixotropic gel forming.     | λ-Carrageenan: highest anionic charge, high solubility, but no gelling. K, τ-Carrageenan: Acid-catalyzed hydrolyses, especially at higher temperature and pH < 3. | Acid-catalyzed hydrolyses, especially at higher temperature and pH < 3. Acid-catalyzed hydrolyses, especially at higher temperature and pH < 3. |
elastic gel is formed with K+,Ca2+, thermoreversible gel forming Release by erosion (physical contact- Scentcaps®), effective against HPV (human papilloma virus)

| Agarose     | Soluble in hot water swelling, Thermoreversible gelation (at ≈37 °C) with hysteresis | Poor biodegradability | 45 |

**Evaluation of Microspheres**

**Particle size and shape**
Considering the microspheres, the traditional SEM (scanning electron microscopy) and LM (light microscopy) approaches are the most extensively employed. Both approaches can be used to identify the shape and exterior structure of microspheres. In the case of double walled microspheres, light microscopy allows for precise control of coating conditions. The architecture of the microspheres may be seen before and after coating, and the alterations can be assessed microscopically. In comparison to light microscopy, scanning electron microscopy has a better resolution.

**Angle of contact**
The angle of contact is measured to determine the wetting property of the micro particle carrier. The nature of the microspheres is determined by their hydrophobicity or hydrophilicity. This thermodynamic feature is unique to the solid and is influenced by the adsorbed component's existence. The angle of contact is measured at the solid/air/water interface.

**Isoelectric point**
The device used to assess the electrophoretic mobility of the microspheres is micro electrophoresis, from which the isoelectric point can be calculated. The mean velocity at different Ph values ranging from 3 to 10 is computed by monitoring the time of travel of a particle across a distance of 1 mm. This information can be used to determine the particle's electrical mobility. The electrophoretic mobility of microspheres can be linked to the surface charge, ionizable behavior, or ion absorption nature of the microspheres.

**Density determination**
The density of the microspheres can be determined using the multi volume pychnometer. The correctly weighted sample in a cup is inserted into the multi volume pychnometer. Helium is put into the chamber at a steady pressure and allowed to expand. The pressure within the chamber decreases as a result of this expansion. The two successive readings of the pressure reduction at various beginning pressures are documented. The density and volume of the microsphere's carrier are calculated using two pressure readings.

**Density of the bulk:**
With the use of a funnel, a precisely weighed sample of microspheres is gently placed into a 10 ml graduated cylinder. The original volume is usually noted. If required, carefully level the microspheres without compacting them, and read the apparent volume V0, which is still unsettled, to the nearest graduated unit. Calculate the bulk density in g/cm³ by the formula.

\[ Df \cdot M = V0 \]

Where Df is bulk density, M is weight of samples in grams and V0 is volumes of sample in cm³.
**Tapped Density:**
The tapped density is obtained by dividing the mass of a powder by the tapped volume in cm$^3$. The sample of microspheres is carefully introduced into a 10 ml graduated cylinder. The cylinder is dropped at 2-second intervals onto a hard wood surface 100 times from a height of 1 inch. The tapped density of each formulation is then obtained by dividing the weight of sample in grams by the final tapped volume in cm$^3$ of the sample contained in the cylinder. It is calculated by using equation given below:

$$D_M = \frac{V_p}{M}$$

Where $D_M$ is bulk density, $M$ is weight of samples in grams and $V_p$ is final tapped volumes of granules in cm$^3$.

**Compressibility index**
It is also calculated through consolidation index of Carr using this formula:

Carr's index = Tapped density - Bulk density / Tapped density $\times 100$

**Physical appearance**
All the prepared microspheres were observed visually for color and uniformity of size.

**Percent yield**
Percentage yield of the prepared microsphere is calculated using the following equation.

$$\% \text{ yield} = \frac{\text{Weight of dried microspheres}}{\text{Amount of drug} + \text{Amount of polymer}}$$

**Swelling index**
Swelling index of dried microspheres was calculated by this formula:

$$\text{Swelling Index} = \frac{\text{Initial weight} - \text{Final weight}}{\text{Initial weight}} \times 100$$

**Fourier Transform-Infrared Spectroscopy**
Fourier Transform Infrared Spectroscopy is utilized to determine the deterioration of the carrier system's polymeric matrix. ATR [alternated total reflectance] is used to investigate the surface of the microspheres. The IR beam travelling through the alternating total reflectance cell reflected multiple times through the sample, resulting in mostly surface material IR spectra. The alternating total reflectance-Fourier Transform-Infrared Spectroscopy gives information about the surface composition of the microspheres depending on the manufacturing techniques and conditions.

**Chemical analysis using electron spectroscopy**
The surface chemistry of the object was studied using ESCA [Electron spectroscopy for chemical analysis]. It is possible to identify microspheres. Electron spectroscopy for chemical analysis gives a method for determining the atomic composition of a surface. Identifying the surficial degradation of the biodegradable microspheres, the spectra obtained using electron spectroscopy for chemical analysis can be used.

**Entrapment efficiency**
By allowing the washed microspheres to lysate the capture efficiency of the microspheres or the percent entrapment can be determined. To the determination of active constituents asper monograph requirement the lysate is then subjected. By using the following equation, the percent encapsulation efficiency is calculated by the formula:

$$\% \text{ Entrapment} = \frac{\text{Actual content}}{\text{Theoretical content}} \times 100$$

**Applications**
**Medical application**
1. Release of proteins, hormones and peptides over extended period of time.
2. Gene therapy with DNA plasmids and also delivery of insulin.
3. Vaccine delivery for treatment of diseases like hepatitis, diphtheria, birth control.
4. Targeting tumor vessels, targeting of tumor cells, antigens, by intra-arterial application.
5. Tumor targeting with doxorubicin and also treatments of leishmaniasis.
6. Magnetic microspheres can be used for stem cell extraction and bone marrow purging.
7. Used in isolation of antibodies, toxin extraction by affinity chromatography.
8. Used for various diagnostic tests for infectious diseases like bacterial, viral, and fungal
Microspheres in vaccine delivery
Protection against the microorganism or its harmful product is a requirement of a vaccination. An ideal vaccine must meet the following criteria: efficacy, safety, ease of use, and cost. The question of safety and minimizing adverse reactions is a difficult one. The degree of antibody response generation and the issue of safety are both intimately related to the technique of application. Biodegradable vaccine delivery technologies for parenteral vaccinations may be able to address the shortcomings of traditional vaccines. Parenteral (subcutaneous, intramuscular, intradermal) carriers are appealing because they provide a number of benefits, including:
1. Improved antigenicity by adjuvant action
2. Modulation of antigen release
3. Stabilization of antigen.
4. Targeting using micro particulate carriers

Surface modified microspheres
Different approaches have been utilized to change the surface properties of carriers to protect them against phagocytic clearance and to alter their body distribution patterns. The most studied surface modifiers are:
1. Antibodies and their fragments
2. Proteins
3. Mono-, oligo- and polysaccharides
4. Chelating compounds (EDTA, DTPA or Desferroxamine)
5. Synthetic soluble polymers

Surface modified microspheres
Different approaches have been utilized to change the surface properties of carriers to protect them against phagocytic clearance and to alter their body distribution patterns. The most studied surface modifiers are:
1. Antibodies and their fragments
2. Proteins
3. Mono-, oligo- and polysaccharides
4. Chelating compounds (EDTA, DTPA or Desferroxamine)
5. Synthetic soluble polymers

Monoclonal antibodies mediated microspheres
Monoclonal antibodies are extremely specific molecules. This extreme specificity of monoclonal antibodies (Mabs) can be utilized to target microspheres loaded bioactive molecules to selected sites. The Mabs can be attached to microspheres by any of the following methods
1. Non-specific adsorption
2. Specific
3. Direct coupling
4. Coupling via reagents

Imaging
Microspheres have been examined extensively and have been employed for targeted applications. Radio-labeled microspheres can be used to imaging a variety of cells, cell lines, tissues, and organs. The particle size range of microspheres is a key component in deciding which sites can be imaged. The particles injected intravenously in a vein other than the portal vein will become caught in the lungs' capillary bed. Using tagged human serum albumin microspheres, this phenomenon is used for scientific graphic imaging of tumour masses in the lungs.

Topical porous microspheres
Microsponges are porous microspheres with a network of linked voids ranging in size from 5 to 300 micrometers. These micro sponges can entrap a wide range of active compounds, including emollients, perfumes, and essential oils, among others. These porous microspheres with active chemicals can be used in creams, lotions, and powder formulations. Microsponges are non-collapsible structures with a porous surface that allows active substances to be released gradually.

Microspheres in Gene delivery:
Viral vectors, cationic liposomes, polycation complexes, and microencapsulated systems are all examples of gene delivery systems. Because viral vectors are very effective and have a large range of cell targets, they are ideal for gene delivery. When employed in vivo, however, they produce immunological responses as well as carcinogenic consequences. Non-viral delivery techniques are being studied for gene therapy to address the limitations of viral vectors. The advantages of a non-viral delivery system are ease of preparation, cell/tissue targeting, low immune response, unrestricted plasmid size, and large-scale, repeatable production. For gene delivery applications, polymer has been employed as a carrier of DNA.
Microspheres for Oral drug delivery
Rabbits were used to test the possibility of polymer films containing diazepam as an oral medication delivery system. The findings suggested that a film made up of a 1:0.5 drug-polymer mixture could be a useful dosage form comparable to existing tablet dosage forms. Polymer’s capacity to form films may allow it to be used in the manufacture of film dosage forms as a substitute for pharmaceutical tablets. Polymer is a unique polymer for oral drug administration applications because of its pH sensitivity and the reactivity of the major amine groups.

Ophthalmic Drug Delivery
Polymer has favourable biological qualities such as bio adhesive, permeability-enhancing capabilities, and unique physico-chemical properties, making it a remarkable material for the construction of ocular drug delivery vehicles. Polymer hydrogels offer better acceptability for ophthalmic delivery, such as suspensions or ointments, due to their elastic properties. Ophthalmic chitosan gels improve adhesion to the mucin that coats the conjunctiva and the corneal surface of the eye, and increase precorneal drug residence times, slowing drug elimination by the lachrymal flow.

Nasal drug delivery:
The mucosa of the nose is an excellent location for bio adhesive medication delivery systems. Polymer-based drug delivery systems, such as micro spheres and gels, have been shown to have high bio adhesion properties and to swell easily when in contact with the nasal mucosa, enhancing drug bioavailability and residence time. For nasal sustained release of vancomycin hydrochloride, various polymer salts such as chitosan lactate, chitosan aspartate, chitosan glutamate, and chitosan hydrochloride are good choices. Nasal delivery of Diphtheria Toxoid encased in chitosan microparticles induces a protective systemic and local immune response against Diphtheria Toxoid, as well as increased IgG production. Nasal formulations have elicited strong serum IgG responses that are comparable to secretory IgA levels, which are superior to parenteral administration of the antibody.

Table:- Microspheres for Nasal Drug Delivery.

| Drug               | Polymer Use                                      | Result                                         |
|--------------------|--------------------------------------------------|------------------------------------------------|
| Gentamicin         | Degradable starch microspheres and lysophosphatidylcholine | Increased nasal absorption                     |
| Insulin            | Degradable starch microspheres and lysophosphatidylcholine | Increased efficiency to nasal route            |
| Human growth hormone | Degradable starch microspheres and lysophosphatidylcholine | Rapid and increased absorption                 |
| Desmopressin       | Starch                                           | Addition of LPC causes a five folds increase in Cmax and two folds increase in bioavailability |
| Haemagglutinin (HA) | Hyaluronic acid esters                           | With mucosal adjuvant serum IgG antibody response as compared to i.m. immunization |

Recent Applications of Controlled Release Microspheres
Microspheres with controlled release are being developed for a variety of purposes, including the delivery of big, fragile medicines like proteins and nucleic acids. The following are a few recent examples.

Vaccines with a Limited-Release Period Vaccination has been extremely effective in managing or even eradicating several key forms of infectious diseases, and new or improved vaccines for AIDS, hepatitis B, anthrax, and SARS are all being studied extensively. The requirement for many administrations is a common issue.

Single-shot vaccine delivery systems should deliver the antigen(s) and adjuvant on a predetermined schedule and retain the antigen's bioactivity throughout the production process and the device's frequently lengthy stay in the body.

Drugs Formulated as Microspheres for Novel Drug Delivery
Table:- List of Drugs Formulated as Microspheres for Novel Drug Delivery

| Category | Drug | References |
|----------|------|------------|
|          |      |            |
### Marketed Products of Microspheres:

**Table:** List of Marketed Microspheres Drug Products.

| Sr. No. | Drug                | Technology       | Commercial Name                     |
|---------|---------------------|------------------|--------------------------------------|
| 1       | Bromocriptine       | Spray drying     | Parlodel LARTM                       |
| 2       | Triptorelin         | Phase separation | Trelstar Depot, DecapeptylR SR       |
| 3       | Octreotide          | Phase separation | SandostatinR LAR                     |
| 4       | Nalrexon            | Double emulsion  | Vivitrol                             |
| 5       | Lanreotide          | Phase separation | Somatuline                           |
| 6       | Somatropin          | Spray drying     | Nutropin                             |
| 7       | Leuprolide          | Double emulsion  | Leupron Depot                        |
| 8       | Risperidone         | Double emulsion  | Risperdal, Consta                    |
| 9       | Pantoprazole        |                  | Pratonix                             |
| 10      | Sulphur Hexafluoride|                  | Lumason                              |
| 11      | Human Albumin       |                  | Optison                              |
| 12      | Tretinoin           |                  | Altinac                              |
| 13      | Perflutren          |                  | Definity                             |
| 14      | Triamcinolone Acteonid |            | Zilretta                             |
| 15      | Minocycline         |                  | Arestin                              |

1. Anticancer: Fluorouracil, Cisplastin, Mitoxantrone, Oxantrazol
2. NSAID: Acelofenac, Ibuprofen, Piroxicam, Flurbiprofen
3. Antibiotic: Cefdinir, Amoxicillin, Gentamicin
4. Anti-inflammatory: Indomethacin, Diclofenac sodium, Ketoprofen
5. Cardiac agent: Telmisartan, Nifedipine, Propranolol, Diltiazem
6. Steroidal: Progesterone
7. Anti-diabetic: Insulin
8. Diuretics: Furosemide
9. Hypoglycemic agents: Glipizide, Vidalgiptin
10. Anti-tuberculosis agent: Rifabutin
11. Anti-HIV: Abacavir Sulphate
12. Bipolar Disorder: Lithium Carbonate
13. SNRIs: Venlafaxine hydrochloride
14. Bronchodilators: Salbutamol
15. K+ channel activator: Nicorandil
16. Hypolipidemic agents: Fluvastatin Sodium
17. Proton pump inhibitors: Rabeprazole Sodium
18. Xanthines: Theophylline

**ISSN:** 2320-5407  
**Int. J. Adv. Res.** 9(12), 903-922
Conclusion:
Microspheres have been identified as one of the best innovative drug delivery systems, with the benefit of target selectivity and improved patient compliance. Its applications are vast, as it is employed not only for drug delivery but also for imaging malignancies, detecting biomolecular interactions, and so on.

Microspheres will play a central role in novel drug delivery in the future, particularly in diseased cell sorting, diagnostics, gene & genetic materials, safe, targeted, and effective in vivo delivery, and supplements as miniature versions of diseased organs and tissues in the body, thanks to the combination of various other strategies.

References:
1. Patil NV, Wadd NV, Thorat SS, UpadhyeShashikantSudarshan. Microspheres: A Novel Drug Delivery System, American Journal Of Pharmtech Research(2020), 286
2. Priya Shukla, C.H.S. Vijaya Vani. Review Article on Microspheres, International Journal of Pharmacy And Analytical Research(2015), 291.
3. A. Krishna Sailaja, Anusha K, Jyothika M. Biomedical applications of Microspheres, Journal of Modern Drug Discovery And Delivery Research (2015), 1
4. Sarlesh Rajput, Preeti Agrawal, Ashish Pathak, Nikhil Shrivastava, Satyendra Singh Baghel, Rajendra Singh Baghel. A Review On Microspheres: Method Of Preparation and Evaluation, World Journal Of Pharmacy And Pharmaceutical Sciences,(2012), 424–426.
5. Harsh Bansal, SimarPreet Kaur, Atul Kumar Gupta. Review Article-Microspheres: Method Of Preparation And Applications; A Comparative Study, International Journal Of Pharmaceutical Sciences Review And Research, (2011), 70-72
6. Jain N K, Controlled and Novel drug delivery, (2004), 236-237, 21.
7. Sinha V R, Bansal K, Kaushik R, Kumria R, Trehan A. Polycapro lactone microspheres and nanospheres, International Journal of Pharmaceutics (2004) 278 1–23.
8. Sinha V R, Singla A K, Wadhawan S ,Kaushik R,Kumria R, Bansal K, Dhawan S, Chitosan microspheres as a potential carrier for drugs, International Journal of Pharmaceutics274:2004, 1–33.
9. Jayaprakash S, Halith S M, Mohamed Firthouse P U, Kulaturanpillai K, Abhijith, Nagarajan M. Preparation and evaluation of biodegradable microspheres of methotrexate. Asian J Pharm,3;2009,26-9.
10. GohelMukesh C, Parikh R K, Stavan, A Spray drying a review, pharmainfo, 7;2009, 5.
11. Swarbrick b j, Spray drying and Spray Congealing of Pharmaceuticals, In: Encyclopedia of Pharmaceutical Technology, Marcel Dekker. 1992, 207-221.
12. Koff US patent (March 21963) 3,080,292. Volume 10, Issue 1, September – October 2011; Article-012 ISSN 0976 – 044X International Journal of Pharmaceutical Sciences Review and Research Page 77 Available online at www.globalresearchonline.net
13. John P M, Becker C H. J. Pharm Science.(1968)57, 584.
14. He P, Davis, S S, Illum, L,Chitosan microspheres prepared by spray drying. Int. J. Pharm,187;1999a,53–65.
15. Ozturk, A.G.; Ozturk, S.S.; Palsson, B.O.; Wheatley, T.A.; Dressman, J.B. Mechanism of release from pelletscoated with an ethylcellulose-based film. J. Control. Release 1990, 14, 203–213.
16. Tang, E.S.K.; Chan, L.W.; Heng, P.W.S. Coating of multiparticulates for sustained release. Am. J. Drug Deliv.2005, 3, 17–28.
17. Prajapati, V.D.; Jani, G.K.; Kapadia, J.R. Current knowledge on biodegradable microspheres in drug delivery. ExpertOpin. Drug Deliv. 2015, 12, 1283–1299. [PubMed]
18. Doty, A.C. Mechanistic Analysis of In Vivo and In Vitro Drug Release From PLGA Microspheres. Ph.D. Thesis, University of Michigan, Ann Arbor, MI, USA, 2015.
19. Bennet, D.; Kim, S.E.I. Application of Nanotechnology in Drug Delivery. In Polymer Nanoparticles for SmartDrug Delivery; Sezer, A.D., Ed.; InTechOpen: London, UK, 2014; ISBN 978-953-51-1628-8 b.
20. Fook, M.; Zilberman, M. Drug delivery from gelatin-based systems. Expert Opin. Drug Deliv. 2015, 12, 1547–1563.
21. Rowe, R.C.; Sheskey, P.; Quinn, M. Handbook of Pharmaceutical Excipients, 7th ed.; Rowe, R.C., Sheskey, S.J., Cook, W.G.F.M., Eds.; Pharmaceutical Press: London, UK, 2009; ISBN 978-0857110275.
22. Inada, A.; Oue, T.; Yamashita, S.; Yamasaki, M.; Oshima, T.; Matsuyama, H. Development of highly-dispersible complexes between coenzyme Q10 and protein hydrolysates. Eur. J. Pharm. Sci. 2019, 136.
23. Ju, Z.Y.; Kilara, A. Gelation of pH-Aggregated Whey Protein Isolate Solution Induced by Heat, Protease, Calcium Salt, and Acidulant. J. Agric. Food Chem. 1998, 8561,
24. Peng, Z.G.; Hidajat, K.; Uddin, M.S. Adsorption of bovine serum albumin on nanosized magnetic particles. J. Colloid Interface Sci. 2004, 271, 277–283.
25. Bouman, J. Controlled Release from Zein Matrices: Interplay of Drug Hydrophobicity and pH. Pharm. Res. 2016, 33, 673–685. [PubMed]
26. Yong, Z.; Lili, C.; Feng, L.; Nianqiu, S.; Chunlei, L.; Xianghui, Y.; Yan, C.; Wei, K. Design, fabrication and biomedical applications of zein-based nano/micro-carrier systems. Int. J. Pharm. 2016, 512, 191–210.
27. Lopes-da-Silva, J.A.; Monteiro, S.R. Gelling and emulsifying properties of soy protein hydrolysates in the presence of a neutral polysaccharide. Food Chem. 2019, 294, 216–223. [CrossRef] [PubMed]
28. Shah, A.V.; Serajuddin, A.T.M.; Mangione, R.A. Making All Medications Gluten Free. J. Pharm. Sci. 2018, 107, 1263–1268. [CrossRef] [PubMed]
29. Ranjha, N.M.; Khan, H. Encapsulation and characterization of controlled release flurbiprofen loaded microspheres using beeswax as an encapsulating agent. J. Mater. Sci. Mater. Med. 2010, 21, 1621–1630. [PubMed]
30. Milanovic, J.; Manojlovic, V.; Levic, S.; Rajic, N.; Nedovic, V.; Bugarski, B. Microencapsulation of Flavors in Carnauba Wax. Sensors 2010, 10, 901–912.
31. Khor, C.M.; Ng, W.K.; Kanaujia, P.; Chan, K.P. Hot-melt extrusion microencapsulation of quercetin for taste-masking. J. Microencapsulation. 2017, 34, 2048.
32. Gopal, K.; Singh, K.; Halder, S.; Pati, S.; Wang, J. Microencapsulation of Paraffin Wax Microspheres with Silver. Def. Sci. J. 2018, 68, 218–224.
33. Rabani, F.; Aziz, A.; Jai, J.; Raslan, R.; Subuki, I. Microencapsulation of citronella oil by complex coacervation using chitosan-gelatin (b) system: Operating design, preparation and characterization. In MATEC Web of Conferences; EDP Sciences: Les Ulis, France, 2016.
34. Hussain, S.A.; Abdelkader, H.; Abdullah, N.; Kmaruddin, S. Review on micro-encapsulation with Chitosan for pharmaceuticals applications. MOJ Curr. Res. Rev. 2018, 1, 77–84.
35. Cunha, L.; Rodrigues, S.; Rosa, A.M.; Faleiro, L.; Buttini, F.; Grena, H. Inhalable chitosan microparticles for simultaneous delivery of isoniazid and rifabutin in lung tuberculosis treatment. Drug Dev. Ind. Pharm. 2019, 45, 1313–1320.
36. Lim, S.T.; Martin, G.P.; Berry, D.J.; Brown, M.B. Preparation and evaluation of the in vitro drug release properties and mucoadhesion of novel microspheres of hyaluronic acid and chitosan. J. Control. Release 2000, 66, 281–292.
37. Jia, X.; Yeo, Y.; Clifton, R.J.; Jiao, T.; Kohane, D.S.; Kobler, J.B.; Zeitels, S.M.; Langer, R. Hyaluronic Acid-Based Microgels and Microgel Networks for Vocal Fold Regeneration. Biomacromolecules 2006, 7, 3336–3344. [PubMed]
38. Eraso, M.O.; Anibal, H. Use of Starches and Milk Proteins in Microencapsulation. Int. J. Veg. Sci. 2014, 20, 289–304.
39. Prabahanan, M. Prospective of guar gum and its derivatives as controlled drug delivery systems. Int. J. Biol. Macromol. 2011, 49, 117–124.
40. Kaity, S.; Isaac, J.; Ghosh, A. Interpenetrating polymer network of locust bean gum-poly (vinyl alcohol) for controlled release drug delivery. Carbohydr. Polym. 2013, 94, 456–467. [PubMed]
41. Street, K.; Davé, V.; McCarthy, S. Review of konjacglucomannan. J. Polym. Environ. 1997, 5, 237–242.
42. Liu, J.; Xu, Q.; Zhang, J.; Zhou, X.; Lyu, F.; Zhao, P. Preparation, composition analysis and antioxidant activities of konjac. Carbohydr. Polym. 2015, 130, 398–404. [PubMed]
43. Necas, J.; Bartosikova, L. Carrageenan: A review. Vet. Med. 2013, 58, 187–205.
44. Sharratt, M.; Grasso, P.; Carpanini, F.; Gangolli, S.D. Carrageenan ulceration as a model for human ulcerative colitis. Lancet 1971, 297, 192–193.
45. Mano, F.; Reis, R.L.; Gasperini, L. Natural polymers for the microencapsulation of cells. J. R. Soc. Interface 2014, 11, 2014-817.
46. Batubara, I.; Rahayu, D.; Mohamad, K. Prasetyaningtyas, W.E. Leydig Cells Encapsulation withAlginate-Chitosan: Optimization of Microcapsule Formation. J. Encapsulation Adsorpt. Sci. 2012, 2,15–20.
47. Capretto, L.; Mazzitelli, S.; Luca, G.; Nastruzzi, C. Preparation and characterization of polysaccharidemicrbeads by a microfluidic technique: Application to the encapsulation of Sertoli cells. Acta Biomater. 2010, 6, 429–435. [PubMed]
48. Shaddel, R.; Hesari, J.; Azadam-damirchi, S.; Hamishehkar, H. Use of gelatin and gum Arabic forencapsulation of black raspberry anthocyanins by complex coacervation. Int. J. Biol. Macromol. 2017, 107,1800–181015. He P, Davis, S S, Illum, L. Sustained release chitosan microspheres prepared by novel spray drying methods J Microencapsul,16;1999b, 343–355
49. Giunchedi P, Conti B, Maggi L, Conte U, Cellulose acetate butyrate and polycaprolactone for ketoprofen spray-dried microsphere preparation J Microencapsul.11;1994, 381–393.
50. Remington, Oral Solid Dosage Forms, The Science and Practice of Pharmacy,04;1995, 1627-1628
51. Bodmeier R, Wang J, Bhagwayar H, Microencapsul, pharm. sci, 9;1992,89–98
52. Bogataj M, Mrhar A, Grabnar I, Rajtman Z, Bukovec P, Sric S, Urlerb U. The influence of magnesium stearate on the characteristics of mucoadhesive microspheres, Microencapsul J pharm. sci. 17:2000,499–508
53. Keykyoon “Kevin” Kim and Daniel W-Pack, Microspheres for Drug Delivery, University of Illions at Urbana-Champaign, pg 20-22, 25-28
54. R.P. Batycky, J. Hanes, R. Langer, and D.A. Edwards. A theoretical model of erosion and macromolecular drug release from biodegrading microspheres. J. Pharm. Sci., 86:1464–1477, 1997.
55. M. Frangione-Beebe, R.T. Rose, P.T. Kaumaya, and S.P. Schwendeman. Microencapsulation of a synthetic peptide epitope for HTLV-1 in biodegradable poly(D,L-lactide-co-glycolide) microspheres using a novel encapsulation technique. J. Microencapsul., 18:663–677, 2001.
56. I.J. Castellanos, K.G. Carraquillo, J.D. Lopez, M. Alvarez, and K. Griebenow. Encapsulation of bovine serum albumin in poly(lactide-co-glycolide) microspheres by the solid-in-oil-in-water technique. J. Pharm. Pharmacol., 53:167–178, 2001.
57. K. Fu, R. Harrell, K. Zinski, C. Um, A. Jaklenec, J. Frazier, N. Lotan, P. Burke, A.M. Klibanov, and R. Langer. A potential approach for decreasing the burst effect of protein from PLGA microspheres. J. Pharm. Sci., 92:1582–1591, 2003.
58. J. Hanes, M. Chiba, and R. Langer. Degradation of porous poly(anhydride-co-imide) microspheres and implications for controlled macromolecule delivery. Biomaterials, 19:163–172, 1998.
59. W. Jiang and S.P. Schwendeman. Stabilization and controlled release of bovine serum albumin encapsulated in poly(D,L-lactide) and poly(ethylene glycol) microsphere blends. Pharm. Res., 18:878–885, 2001b.
60. M. Sandor, D. Enscoe, P. Weston, and E. Mathiowitz. Effect of protein molecular weight on release from micron-sized PLGA microspheres. J. Control. Rel., 76:297–311, 2001.
61. J. Wang, B.M. Wang, and S.P. Schwendeman. Characterization of the initial burst release of a model peptidemfrom poly(dl-lactide-co-glycolide) microspheres. J. Control. Rel., 82(2–3):289–307, 2002.
62. J. Wang, B.W. Wang, and S.P. Schwendeman. Mechanistic evaluation of the glucose-induced reduction in initial burst release of octreotide acetate from poly(D,L-lactide-co-glycolide) microspheres. Biomaterials, 25:1919–1927, 2004.
63. Y. Tabata and R. Langer. Poly(anhydride) microspheres that display near-constant release of water-soluble model drug compounds. Pharm. Res., 10:391–399, 1993b.
64. B. Amsden. The Production of Uniformly Sized Polymer Microspheres. Pharm. Res., 16(7):1140–1143, 1999a.
65. B. Amsden. The production of uniformly sized polymer microspheres. Pharm. Res., 16:1140–1143, 1999b.
66. B.G. Amsden and M. Goosen. An examination of the factors affecting the size, distribution, and release characteristics of polymer microbeads made using electrostatics. J. Control. Rel., 43:183–196, 1997.
67. N. Leelarasamee, S.A. Howard, C.J. Malanga, and J.K.H. Ma. A method for the preparation of poly(lactic acid) microcapsules of controlled particle size and drug loading. J. Microencapsul., 5:147–157, 1988.
68. L. Rayleigh. Phil. Mag. S.G., 14:184, 1882.
69. P. Sansdrep and A.J. Moes. Influence of manufacturing parameters on the size characteristics and the release profiles of nifedipine from poly(D,L-lactide-co-glycolide) microspheres. Int. J. Pharm., 98:157–164, 1993.
70. K. Shiga, N. Muramatsu, and T. Kondo. Preparation of poly(D,L-lactide) and copoly(lactide-glycolide) microspheres of uniform size. J. Pharm. Pharmacol., 48:891–895, 1996.
71. MielenLengyel, NikolettKallai-Szabo, Vince Antal, AndrasJozsefLaki and IstvanAntal, A Review-Microparticles, Microspheres, and Microcapsules For Advanced Drug Delivery, ScientiaPharmaceutica MDPI (2019), 6-10
72. Jain N.K., Controlled and Novel drug delivery: 04 Edition: 236-237,21.
73. Sinha, v. R.; Agrawal, M. K.; Kumria, R: Influence of formulation and excipient variables on the pellet properties prepared by extrusion spherization. Curr. Drug Delivery:2005:2:1-8.
74. Bodmeier R, Chen H. Preparation and characterization of microspheres containing the antiinflammatory agents, Indomethacin, ibuprofen and ketoprofen. J. Controlled Release; 1989;10: 167175.
75. Kawashia Y, Niwa T, Takeuchi H, Hino T, Itoh Y, Furuyamas: Characterization of
polymorphs of tranilast anhydrate and tranilast monohydrate when crystallized by two solvent change spherical crystallization techniques. J Pharm Sci:1991;81:472–478.
75. Schugens C., Larvelle. N., Nihantn., Grandfils C., Jerome R. and Teysie. P. J.Control.Rel;1994:32:161.
76. Rathone, M.J: “Human buccal absorption I.A method for Estimating the transfer kinetics of drugs W cross the human buccal membrane”. Int.J.pharm:1991a:69:103.
77. Burnside, B.A; Keith, A.P. and snipes, W: “micro porous hollow fibers as a peptide delivery system via the buccal activity”.proceed.inter.symph.control. Rel. Bioact. mater:1989:16:94.
78. Farah Hamad Farah, Magnetic Microspheres: A Novel Drug Delivery System, Journel Of Analytical And Pharmaceutical Research, (2016), 6
79. Birj Mohan Singh Meshram, Ashwini Mishra And Anup Pathak, Formulation And Evaluation Of Microsphere Of Rebiprazole Sodium, International Journal Of Advances in Pharmaceuticals, (2016), 78-79.
80. Formulation And Evaluation Of Microsphere of antiulcer drug using Acacia nilotica gum, International Journal of Health Sciences,(2020), 12
81.Lachman LA, Liberman HA, Kanig JL. The Theory and Practice of Industrial Pharmacy. 3rd edition 1991; Varghese Publishing House, Mumbai, India: P-414-415.
82. Amsden BG, and Goosen M. An examination of the factors affecting the size, distribution, and release characteristics of polymer microbeads made using electrostatics. J. Control. Rel.1997; 43:183 – 196.
83. Vikrant Deshmukh, ShubhangiWarad, Rahul Solunke, ShitalWalunj,ShivaprasadPalve, Ganesh Jagdale, Microspheres: as new drug delivery system, Vol 2 .Issue 6,pg 4504- 4519
84. A.KrishnaSailija, Anusha k, Jyotica M, Biomedical Applications Of Microspheres, Journal Of Modern Drug Discovery And Drug Delivery Research,(2015), 2-4
85.Nagpal M, Midha K, Arora S: Microspheres: A recent update. International Journal of RecentScientific Research: 2015;5(3):543-66.
86. Li Y P, Machida T Y, Sannan T, Nagai T., Preparation of chitosan microspheres containing fluorouracil using the 'dryin-oil' method and its release characteristics. STP Pharm. Sci. 1:1991:363–368
87. Berthold A, Cremer K, KreuterJ, Influence of crosslinking on the acid stability and physicochemical properties of chitosan microspheres. STP Pharm. Sci.6;1996 b,358–364
88. AlagusundaramM, Madhu S C C , Umashankari K, Attuluri V B, Lavanay C , Ramkanth S, Microspheres as A Novel Drug Delivery System,Chentech,13;2009. 526-534,
89. Bodmeier R, Wang J, Bhagwatwar H J, Microencaps. J pharm.sci9;1992,99
90. AlagusundaramM, Madhu S C C, Umashankari K, Attuluri V B, Lavanay C, Ramkanth S, Microspheres as A Novel Drug Delivery System,Chentech,13;2009. 526-534,
91. Swati P. Shah, Preparation And Evaluation Of Tableted Microspheres Of Ibuprofen Encapsulated in Beeswax, Thesis to University Of Georgia, 2004
92. Raya Krishna SEELAM, EliyasKadi ABAFITA, Preparation and Evaluation Of Alginate Microspheres of Piroxicam for controlled release, Gaziantep Medical Journal 2016;22(1):27-32
93. Prashant Patil, Santosh Singh, Janardhan Sarvanan,Preparation and Evaluation Of Microspheres of Flurbiprofen ,International Journal Of Pharmaceutical Sciences and Research, 2018, Vol.9(12):5388-5293
94. Raju Bhatula, M.Nirmala, K. Ramadevi, S. Janet Beula, Formulation And Evaluation Of Microspheres Of Cefdinir, Asian Journal Of Pharmaceutical Research, Vol 1, Issue 1, 65-70.
95. Sinha V R, Bansal K, Kaushik R, Kumria R, Trehan A. Polycaprolactone microspheres and nanospheres, International Journal of Pharmaceutics (2004) 278 1–23.
96. Jameela S R, Jayakrishnan A, Glutaraldehyde crosslinked chitosan microspheres as a long acting biodegradable drug delivery vehicle: studies on the in vitro release of mitoantrone and in vivo degradation of microspheres in rat muscle. Biomaterials 16;1995, 769–775.
97. Hassan E E, Parish R C, Gallo J M, Optimized formulation of magnetic chitosan microspheres containing the anticancer agent, oxantrazole. Pharm. Res.9;1992, 390–397.
98. Shah S, Qaqish R, Patel V, Amiji M, Evaluation of the factors influencing stomach-specific delivery of antibacterial agents for Helicobacter pylori infection. J. Pharm. Pharmacol.51,1999, 667–672.
99. Praveen Kumar Gaur, Shikha Mishra, Meenakshi Rajput, Formulation And Evaluation Of Controlled release of Telmisartan Microspheres, Journal Of Food And Drug Analysis 22(2014)542-548.
101. Bayomi M A, al-Suwayeh S A, el-Helw A M, Mesnad A F. Preparation of casein–chitosan microspheres containing diltiazem hydrochloride by an aqueous coacervation technique. Pharm. Acta Helv. 73; 1998, 187–192.

102. Jameela S R, Kumary T V, Lal A V, Jayakrishnan A. Progesterone-loaded chitosan microspheres: a long acting biodegradable controlled delivery system. J. Control Rel. 52; 1998, 17–24.

103. Huang H, Tian H, Li X, Zhao G. Hypoglycemic effect of chitosan-microcapsulated insulin on the blood glucose level of streptozotocin-diabetic Wistar rats. Sheng Wu Yi Xue Gong Cheng Xue Za Zhi, 18; 2008, 425–427.

104. Akbuga J, Durmaz G, Akbuga J, Durmaz G. Preparation and evaluation of crosslinked chitosan microspheres containing furosemide. Int. J. Pharm. 111; 1994, 217–222.

105. S. Mohapatra, S. Sen, S. C. Si. Preparation and evaluation of Glipizide Microspheres using Mucoadhesive Polymers. IJPSR, 2013.

106. Nighute A B and Bhide S B. Preparation and evaluation of Rifamputin Microspheres using Eudragit Polymers, RJPT, Vol 2 (4), 2009.

107. N. Chandrasekaran, M. Balamurugan. Formulation, Characterisation and In-vitro evaluation of Abacavir Sulphate loaded Microspheres, Research J. Pharm. And Tech., 6(7); July 2013.

108. D. V. Gowada and H. G. Shivkumar. Preparation and Evaluation Of Waxes/Fats Microspheres loaded with Lithium Carbonate for Controlled Release, IJPS, 2007, 251.

109. Sabarinathan, R. Formulation And Evaluation Of Sustained Release Microspheres of Venlafaxine Hydrochloride, Tamil Nadu Medical University, May 2012.

110. L Pachuau, S Sarkar and B Mazumdar. Formulation And evaluation of matrix microspheres for simultaneous delivery of salbutamol sulphate and theophylline, Tropical Journal of Pharmaceutical Research, June 2008, 7(2); 955-1002.

111. Keyur S Patel, Mandev B Patel. Preparation and evaluation of Chitosan Microspheres containing Nicorandil, IJPI, Jan 2014, Vol 4, Issue 1, 32.

112. Venkatesh Dp, Roopa Karki, Sajal Kumar Jha, L.A. Geetha. Formulation and evaluation of Microspheres of Fluvastatin Sodium, IJDD&R, June 2012, 4(2), 306-314.

113. Brij Mohan Singh Meshram, Ashwini Mishra and Anupam Pathak. Formulation and evaluation of Microspheres of Rebiprazole Sodium, IJAP, Vol 5, Issue 3 (2016), 75.